MedMira Announces Grant of Employee Stock Options

MedMira Announces Grant of Employee Stock Options
Halifax, Nova Scotia, January 5, 2009 – MedMira Inc., (“MedMira”) (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and solutions, today announced that the Board of Directors granted a total of 1,585,000 options to purchase commons shares to its employees. Of this total, 450,000 options were issued to officers and managing directors. The options are at an exercise prices of
.10 per share and are exercisable for a period of five years. The grant is subject to the approval of the TSX Venture Exchange.
About MedMira
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company’s tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company’s tests are sold under the Reveal®, MiraWell®, MiraCare™ and Multiplo™ brands in global markets. MedMira’s rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira’s corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira’s website at www.medmira.com.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company’s current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.
MedMira Contacts:
Dr. James Smith, Investor Relations & Corporate Affairs
Tel: 902-450-1588
Email: [email protected]
Andrea Young, Corporate Communications
Tel: 902-450-1588
Email: [email protected]